Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptors blockers

US6414030B1 · kind B1 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Klaus Wirth · Frankfurt am Main, DE
• Heinrich Englert · Hofheim, DE
• Helmut Bohn · Schöneck, DE
• Heinz Gogelein · Frankfurt am Main, DE
• Holger Heitsch · Hofheim, DE
• Uwe Gerlach · Hattersheim, DE

Key dates

• Filing date: Nov 9, 2001
• Grant date: Jul 2, 2002
• Expiry date: Nov 9, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C08K5/5406
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Substituted benzenesulfonylureas and -thioureas of the formula I in which R1, R2, E, X, Y and Z have the meanings described herein, show effects on the autonomous nervous system. The invention relates to the use of the compounds of the formula I in the treatment and prophylaxis of dysfunctions of the autonomous nervous system, in particular of vagal dysfunctions, for example in the case of cardiovascular diseases. The invention also relates to the use of compounds of the formula I in combination with beta-receptor blockers and to products and pharmaceutical preparations which comprise at least one compound of the formula I and at least one beta-receptor blocker, and to novel compounds.